Core Viewpoint - InMed Pharmaceuticals has published a peer-reviewed study demonstrating the anti-inflammatory effects of cannabinol (CBN) through modulation of the endocannabinoid system, indicating its potential therapeutic applications for inflammatory skin diseases [2][4]. Company Overview - InMed Pharmaceuticals is focused on developing proprietary small molecule drug candidates targeting CB1/CB2 receptors, with a pipeline that includes programs for Alzheimer's disease, ocular conditions, and dermatological indications [6]. Study Findings - The study, conducted in collaboration with Dr. Mauro Maccarrone, found that CBN can prevent keratinocyte inflammation via TRPV1, express mitogen-activated protein kinases, modulate endocannabinoid-regulating enzymes, increase CB1 expression, and alter cytokine release by reducing pro-inflammatory cytokines (IL-8, IL-12, IL-31) while increasing the anti-inflammatory cytokine IL-10 [3][4]. - The anti-inflammatory activity of CBN suggests its potential to regulate epidermal functions and provide protective roles in the skin [4]. Expert Commentary - Dr. Mauro Maccarrone highlighted the significance of the study in providing scientific evidence for CBN's anti-inflammatory properties, supporting its therapeutic and cosmetic applications in treating inflammatory skin conditions [4]. - Dr. Eric Hsu emphasized the importance of understanding the endocannabinoid system in the context of various diseases and how rare cannabinoids may modulate inflammation [4].

Core Viewpoint - InMed Pharmaceuticals reported positive progress in its pharmaceutical programs, particularly with its Alzheimer's treatment candidate INM-901, and announced financial results for the first quarter of fiscal 2025, highlighting a commitment to enhancing shareholder value through strategic opportunities and operational improvements [3][4]. Financial Results - For the first quarter ended September 30, 2024, InMed reported revenues of $1.3 million from its BayMedica commercial business, a 40% increase from $0.9 million in the same period last year [8]. - The company recorded a net loss of $1.68 million for the quarter, compared to a net loss of $2.54 million in the same period of the previous year, indicating an improvement in financial performance [13]. - Research and development expenses decreased to $0.8 million from $1.3 million year-over-year, primarily due to reduced spending on external contractors and patent fees [9]. - As of September 30, 2024, the company had cash and cash equivalents of $5.6 million, down from $6.6 million at the end of the previous quarter [10]. Pharmaceutical Development Programs - INM-901, targeting Alzheimer's disease, showed robust progress with positive behavioral data from long-term preclinical studies, achieving statistical significance in certain criteria [3][4]. - The drug can be administered orally, achieving therapeutic levels in the brain comparable to intraperitoneal injection, which is significant for its development [4]. - Next steps for INM-901 include further molecular analyses to characterize its mechanisms of action, with data read-out expected in calendar Q4 2024 [5]. - INM-089, aimed at treating dry Age-related Macular Degeneration (AMD), is progressing with additional in vivo preclinical studies and ongoing Chemistry, Manufacturing, and Controls (CMC) activities [6]. Corporate Actions - The company implemented a reverse stock split effective November 14, 2024, to regain compliance with Nasdaq listing requirements, reflecting its commitment to maintaining a major exchange listing [3].

Summary of InMed Pharmaceuticals (INM) Update / Briefing Industry Overview - The discussion centers around the Alzheimer's disease research and development landscape, highlighting the recent advancements in disease-modifying therapies and the challenges faced in clinical trials and drug development [6][7][15]. Key Points and Arguments Advances in Alzheimer's Research - There has been a significant increase in understanding Alzheimer's disease over the past decade, with the first disease-modifying therapies launched in the U.S., Japan, and China [6][7]. - The removal of amyloid from the brains of patients has been achieved, impacting tau levels and disease progression, although the average clinical impact remains limited [15][16][18]. Challenges with Mouse Models - Current mouse models primarily focus on amyloidosis and tauopathy, which do not fully replicate the complexity of Alzheimer's disease [8][9][10]. - The efficacy of treatments is often tested in younger mice, which may not accurately reflect the disease's progression in older adults [10][11]. - Advanced-stage models are necessary to better understand the safety and efficacy of treatments [11][13]. Importance of Biomarkers - The selection of patients for clinical trials has evolved from clinical criteria to biomarker-based criteria, improving the ability to demonstrate clinical efficacy [21][22]. - There is a need for better biomarkers for neuroinflammation, which is still in early development compared to amyloid biomarkers [47][48]. Neuroinflammation as a Target - Chronic neuroinflammation is recognized as a significant factor in Alzheimer's disease, with potential drug targets being explored [32][33][36]. - InMed's compound, INM901, shows promise in modulating neuroinflammation and promoting neurogenesis, with positive results in animal studies [30][51][52]. Diversity in Clinical Trials - Current clinical trials have been criticized for lacking racial and ethnic diversity, which may affect the understanding of drug efficacy across different populations [18][20][60]. Future Directions - The panelists express optimism about the future of Alzheimer's research, emphasizing the need for combination therapies and the potential for repurposing existing drugs [41][65]. - The goal is to transform Alzheimer's from a terminal disease to a chronic condition, improving the quality of life for patients [88][89]. Other Important Content - The discussion highlights the iterative learning process in selecting patients for trials based on biomarkers rather than solely on clinical diagnosis [21][22]. - The role of inflammation in Alzheimer's is complex, with both beneficial and harmful effects depending on the disease stage [40][76]. - The importance of accurate diagnosis and the distinction between Alzheimer's disease and dementia is emphasized [103]. This summary encapsulates the key discussions and insights from the InMed Pharmaceuticals update, focusing on the current state and future directions of Alzheimer's disease research and treatment.

Core Viewpoint - InMed Pharmaceuticals has filed an additional international patent application for its proprietary small molecule drug candidate INM-901, aimed at treating neurodegenerative diseases, including Alzheimer's disease, which addresses significant unmet medical needs [3][4]. Group 1: Patent Application Details - The new PCT patent application includes methods for treating neuronal disorders associated with neurodegeneration and aims to inhibit or slow disease progression by reducing cytotoxicity in affected neurons [4]. - It specifies methods for neuroprotection, stimulating neurogenesis, enhancing activity, and improving cognitive functions, while also addressing inflammation and neuronal function markers [5]. Group 2: Drug Development and Mechanism - INM-901 targets multiple biological pathways related to Alzheimer's disease, demonstrating reduced neuroinflammation and improved neuronal function, indicating potential restoration of damage caused by the disease [7]. - The drug acts as a preferential signaling agonist of CB1/CB2 receptors, showing neuroprotective effects and impacting peroxisome proliferator-activated receptors (PPARs), which are relevant for neurodegenerative disorders [7][8]. - INM-901 can be administered orally, achieving therapeutic levels in the brain comparable to intraperitoneal injection, which may offer advantages over current approved products [8]. Group 3: Company Overview - InMed Pharmaceuticals focuses on developing proprietary small molecule drug candidates targeting CB1/CB2 receptors, with a pipeline that includes programs for Alzheimer's, ocular, and dermatological indications [9].

InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's DiseaseOctober 24, 2024 8:00 AM EDT | Source: InMed PharmaceuticalsVancouver, British Columbia--(Newsfile Corp. - October 24, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced it will be participating in the upcoming Fierce ...

InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory BoardOctober 22, 2024 8:00 AM EDT | Source: InMed PharmaceuticalsVancouver, British Columbia--(Newsfile Corp. - October 22, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the appointment of Dr. Ba ...

Core Viewpoint - InMed Pharmaceuticals reported a financial update for fiscal year 2024, highlighting advancements in its drug development pipeline, particularly for Alzheimer's disease and dry Age-related Macular Degeneration (AMD), alongside a revenue increase for its subsidiary, BayMedica [2][4]. Financial Performance - The company generated $4.6 million in revenues for fiscal year 2024, marking an 11% increase compared to the previous fiscal year [2][10]. - For the year ending June 30, 2024, InMed recorded a net loss of $7.7 million, a slight improvement from a net loss of $7.9 million in the prior year [4][11]. - Cash, cash equivalents, and short-term investments totaled $6.6 million as of June 30, 2024 [4][14]. Drug Development Programs INM-901 - INM-901 is a proprietary small molecule drug candidate targeting multiple biological pathways associated with Alzheimer's disease, showing neuroprotective effects and potential for cognitive function improvement [5][6]. - The program has advanced significantly, with ongoing preclinical studies demonstrating its ability to reduce neuroinflammation and improve neuronal function [5][6]. - The drug can be administered orally, achieving therapeutic levels comparable to intraperitoneal injection, which may offer advantages over current treatments [5]. INM-089 - INM-089 is being developed for the treatment of dry AMD, with preclinical data indicating enhanced neuroprotection of photoreceptors and improved retinal pigment epithelium integrity [6][7]. - The data suggests INM-089 may be particularly effective for geographic atrophy, a more advanced stage of dry AMD [7]. INM-755 - The INM-755 program is focused on dermatological applications, with potential expansion beyond Epidermolysis bullosa (EB) to address chronic, severe itch [8]. Intellectual Property - InMed has strengthened its patent portfolio with the issuance of three new U.S. patents related to formulation, manufacturing processes, and drug delivery [4][9]. BayMedica Subsidiary - BayMedica, the company's commercial subsidiary, achieved $4.6 million in sales for fiscal year 2024, reflecting an 11% increase from the previous year [10][13].

Core Insights - InMed Pharmaceuticals has strengthened its patent portfolio with the issuance of three U.S. patents, enhancing its intellectual property protection for drug candidates targeting high unmet medical needs [2][3]. Patent Portfolio Summary - The company now holds a total of 13 patent families covering new chemical entities, formulations, manufacturing methods, and methods of use [4]. - The newly granted patents include: - A method of use patent for topical cannabinoid formulations in treating epidermolysis bullosa, granted in the U.S., Australia, Japan, and Israel, with pending status in several other jurisdictions [3][4]. - A biosynthesis patent for manufacturing proprietary cannabinoid analogs, granted in the U.S. [3][4]. - An ocular drug delivery formulation patent, granted/allowed in the U.S., Europe, Australia, Japan, and India, with pending status in other jurisdictions [3][4]. Company Focus and Future Plans - InMed is committed to expanding its patent portfolio to protect its novel drug candidates and manufacturing methods, particularly for its INM-901 program targeting Alzheimer's disease and INM-089 for dry Age-related Macular Degeneration [4][5].

Core Insights - InMed Pharmaceuticals Inc. has confirmed INM-901 as an oral formulation for its Alzheimer's disease development programs [1] - Recent preclinical studies show that INM-901 can achieve therapeutic levels in the brain comparable to those obtained through intraperitoneal injection [2][3] - The oral formulation of INM-901 maintains similar drug exposure levels in the brain over a 24-hour period as compared to IP delivery [3] Company Developments - Michael Woudenberg, COO of InMed, expressed excitement over the data confirming that INM-901 can cross the blood-brain barrier as an oral formulation, highlighting its advantages for Alzheimer's treatment [4] - The company is conducting further studies on drug metabolism, dose-ranging, and pharmacokinetics to support an IND submission [6] Market Reaction - Following the announcement, INM stock experienced a significant increase of 241.8%, reaching $0.51 [6]

. . July 30, 2024 8:00 AM EDT | Source: InMed Pharmaceuticals Vancouver, British Columbia--(Newsfile Corp. - July 30, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced positive results from initial data sets from a long-term (7 months of dosing) in vivo preclinical Alzheimer's Disease ("AD") study of INM-901 which confi ...